Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN008 plus TMZ in Newly Diagnosed Glioblastoma
NCT05447195Phase 2
Key facts
- Status
- Unknown
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Countries
- 1
- Modality
- Fc-Fusion Proteins
- Drugs
- asunercept
- Conditions
- glioblastoma (GBM)
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing CAN008 with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
CAN008
CAN008 + RT + TMZ followed by maintenance and monotherapy
Placebo
Placebo + RT + TMZ followed by maintenance and monotherapy
03
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT05447195.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447195.